| Bioactivity | Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats[1][2][3]. |
| Target | VEGF-C/D |
| In Vivo | Sozinibercept 抑制激光诱导脉络膜新生血管 (CNV) 模型中 CNV 病变形成和血管渗漏。此外，Sozinibercept 在 CNV 小鼠模型中表现出与 Aflibercept (HY-108801; Eylea®) 相当的疗效[1][2]。Sozinibercept (玻璃体内注射; 每 4 周一次, 共 4 月) 对 VEGF-C/D 有选择性抑制作用，对链脲佐菌素 (STZ) 诱导大鼠糖尿病视网膜水肿有抑制作用，与 VEGF-A 抑制剂 (Aflibercept) 的抑制作用相当[3]。 |
| Name | Sozinibercept |
| CAS | 2568358-31-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lashkari K, et al. VGX-300, a ‘Trap’for VEGF-C and VEGF-D, Inhibits Choroidal Neovascularization and Vascular Leakage in a Mouse Model of Wet AMD[J]. Investigative Ophthalmology & Visual Science, 2015, 56(7): 4802-4802. [2]. Lashkari K, et al. VEGF-C and VEGF-D Blockade by VGX-300 Inhibits Choroidal Neovascularization and Leakage in a Mouse Model of wet AMD[J]. Investigative Ophthalmology & Visual Science, 2014, 55(13): 1823-1823. [3]. Turunen T, et al. VEGF-C and VEGF-D Inhibition by VGX-300 Effectively Reduces Leukocyte Adhesion and Vascular Leakage in the STZ-Rat Model of Diabetic Retinal Edema[J]. Investigative Ophthalmology & Visual Science, 2019, 60(9): 3667-3667. |